Denali Therapeutics (DNLI) Competitors $15.04 -0.18 (-1.20%) As of 10:13 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock DNLI vs. BEAM, GRFS, RYTM, RNA, ABVX, LEGN, CYTK, NUVL, AXSM, and TGTXShould you be buying Denali Therapeutics stock or one of its competitors? The main competitors of Denali Therapeutics include Beam Therapeutics (BEAM), Grifols (GRFS), Rhythm Pharmaceuticals (RYTM), Avidity Biosciences (RNA), Abivax (ABVX), Legend Biotech (LEGN), Cytokinetics (CYTK), Nuvalent (NUVL), Axsome Therapeutics (AXSM), and TG Therapeutics (TGTX). These companies are all part of the "pharmaceutical products" industry. Denali Therapeutics vs. Its Competitors Beam Therapeutics Grifols Rhythm Pharmaceuticals Avidity Biosciences Abivax Legend Biotech Cytokinetics Nuvalent Axsome Therapeutics TG Therapeutics Denali Therapeutics (NASDAQ:DNLI) and Beam Therapeutics (NASDAQ:BEAM) are both mid-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, media sentiment, risk and dividends. Does the media prefer DNLI or BEAM? In the previous week, Beam Therapeutics had 1 more articles in the media than Denali Therapeutics. MarketBeat recorded 2 mentions for Beam Therapeutics and 1 mentions for Denali Therapeutics. Beam Therapeutics' average media sentiment score of 0.33 beat Denali Therapeutics' score of 0.02 indicating that Beam Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Denali Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Beam Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more volatility and risk, DNLI or BEAM? Denali Therapeutics has a beta of 1.3, indicating that its share price is 30% more volatile than the S&P 500. Comparatively, Beam Therapeutics has a beta of 2.25, indicating that its share price is 125% more volatile than the S&P 500. Do insiders & institutionals hold more shares of DNLI or BEAM? 92.9% of Denali Therapeutics shares are owned by institutional investors. Comparatively, 99.7% of Beam Therapeutics shares are owned by institutional investors. 12.5% of Denali Therapeutics shares are owned by insiders. Comparatively, 3.5% of Beam Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Do analysts rate DNLI or BEAM? Denali Therapeutics currently has a consensus price target of $33.50, suggesting a potential upside of 122.77%. Beam Therapeutics has a consensus price target of $46.40, suggesting a potential upside of 82.96%. Given Denali Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Denali Therapeutics is more favorable than Beam Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Denali Therapeutics 1 Sell rating(s) 1 Hold rating(s) 13 Buy rating(s) 3 Strong Buy rating(s) 3.00Beam Therapeutics 1 Sell rating(s) 2 Hold rating(s) 8 Buy rating(s) 3 Strong Buy rating(s) 2.93 Is DNLI or BEAM more profitable? Denali Therapeutics has a net margin of 0.00% compared to Beam Therapeutics' net margin of -661.31%. Denali Therapeutics' return on equity of -40.79% beat Beam Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Denali TherapeuticsN/A -40.79% -36.39% Beam Therapeutics -661.31%-43.15%-31.06% Which has stronger earnings and valuation, DNLI or BEAM? Beam Therapeutics has higher revenue and earnings than Denali Therapeutics. Beam Therapeutics is trading at a lower price-to-earnings ratio than Denali Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDenali TherapeuticsN/AN/A-$422.77M-$2.80-5.37Beam Therapeutics$60.27M42.57-$376.74M-$4.50-5.64 SummaryDenali Therapeutics beats Beam Therapeutics on 8 of the 15 factors compared between the two stocks. Get Denali Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DNLI and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding DNLI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DNLI vs. The Competition Export to ExcelMetricDenali TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.20B$3.34B$6.13B$10.63BDividend YieldN/A2.29%5.51%4.67%P/E Ratio-5.3722.0086.0727.10Price / SalesN/A409.13587.32183.34Price / CashN/A46.3226.3031.10Price / Book1.769.9813.096.71Net Income-$422.77M-$52.42M$3.30B$276.23M7 Day Performance3.57%6.49%5.49%4.30%1 Month Performance-2.54%12.83%9.27%11.61%1 Year Performance-43.47%26.45%86.14%41.42% Denali Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DNLIDenali Therapeutics4.2615 of 5 stars$15.04-1.2%$33.50+122.8%-46.8%$2.20BN/A-5.37430BEAMBeam Therapeutics2.9165 of 5 stars$23.91+4.1%$46.40+94.1%+10.6%$2.32B$63.52M0.00510GRFSGrifols3.8914 of 5 stars$9.93+1.1%$10.30+3.7%+7.7%$6.75B$7.81B8.4923,822Positive NewsShort Interest ↑RYTMRhythm Pharmaceuticals3.5764 of 5 stars$100.64+1.5%$106.64+6.0%+97.2%$6.59B$130.13M0.00140RNAAvidity Biosciences2.5025 of 5 stars$42.63-0.7%$68.32+60.3%-2.4%$6.27B$10.90M-11.97190ABVXAbivax2.9339 of 5 stars$83.33+0.6%$102.14+22.6%+786.2%$6.26BN/A0.0061News CoverageAnalyst ForecastGap UpLEGNLegend Biotech2.8378 of 5 stars$32.85-1.6%$74.22+125.9%-35.9%$6.16B$627.24M-37.332,609CYTKCytokinetics3.8676 of 5 stars$53.89+6.9%$75.71+40.5%+7.0%$6.03B$18.47M-10.57250Trending NewsAnalyst ForecastInsider TradeNUVLNuvalent3.2618 of 5 stars$84.84+4.2%$119.50+40.9%-20.1%$5.87BN/A0.0040AXSMAxsome Therapeutics4.7953 of 5 stars$117.62+0.7%$177.86+51.2%+38.5%$5.83B$385.69M0.00380TGTXTG Therapeutics4.374 of 5 stars$36.83+3.7%$48.00+30.3%+65.4%$5.63B$329M99.54290Analyst ForecastAnalyst Revision Related Companies and Tools Related Companies Beam Therapeutics Competitors Grifols Competitors Rhythm Pharmaceuticals Competitors Avidity Biosciences Competitors Abivax Competitors Legend Biotech Competitors Cytokinetics Competitors Nuvalent Competitors Axsome Therapeutics Competitors TG Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DNLI) was last updated on 10/7/2025 by MarketBeat.com Staff From Our PartnersMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredU.S. Government Sparking Crypto RallyU.S. Puts GDP on the Blockchain Could this spark the next crypto supercycle? Discover the altcoins poised t...Crypto 101 Media | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Denali Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Denali Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
